Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence (Q33807228)

29 July 2017

1 reference

title

Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence (English)

1 reference

29 July 2017

4

Michael Weller

1 reference

29 July 2017

1

Wolfgang Wick

1 reference

29 July 2017

2

Antje Wick

1 reference

29 July 2017

Markus Weiler

3

1 reference

29 July 2017

publication date

1 June 2011

1 reference

Current Neurology and Neuroscience Reports

29 July 2017

published in

1 reference

29 July 2017

volume

11

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

305-312

1 reference

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Bevacizumab and recurrent malignant gliomas: a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

All roads lead to mTOR: integrating inflammation and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

A novel tool to analyze MRI recurrence patterns in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Will integrin inhibitors have proangiogenic effects in the clinic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Yes and PI3K bind CD95 to signal invasion of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Radiographic patterns of relapse in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Effect of hydrophilic components of the extracellular matrix on quantifiable diffusion-weighted imaging of human gliomas: preliminary results of correlating apparent diffusion coefficient values and hyaluronan expression level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Novel anti-angiogenic therapies for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0184-0

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

21 January 2018

1 reference

12 December 2020

Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Correlation between magnetic resonance imaging and histopathology of intracranial glioma

1 reference

12 December 2020

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

1 reference

12 December 2020

Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.

1 reference

12 December 2020

Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma

1 reference

12 December 2020

10.1007/S11910-011-0184-0

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1005014853

0 references

1 reference